<DOC>
	<DOCNO>NCT02231775</DOCNO>
	<brief_summary>The goal clinical research study compare receive combination dabrafenib trametinib surgery surgery alone patient melanoma . The safety study drug combination also study .</brief_summary>
	<brief_title>Neoadjuvant Adjuvant Dabrafenib Trametinib Patients With Clinical Stage III Melanoma ( Combi-Neo )</brief_title>
	<detailed_description>Study Drug Administration : If participant find eligible take part study , participant receive dabrafenib trametinib 8 week participant surgery . Participant surgery disease grow spread 8 week participant receive study drug . After participant recover surgery eat drink normally , participant continue take study drug additional 44 week . Participant take capsule dabrafenib twice day tablet trametinib one time every day . The dabrafenib trametinib take time morning , second dose dabrafenib take 12 hour later . Participant take capsule tablet cup ( 8 ounce ) water every time , either 1 hour 2 hour eat meal . Participant stop take study drug 1 day surgery , resume take study drug within 1 week surgery . Study Visits : Participants tissue collect surgery routine test . Cycle 1 8 week ( surgery ) Cycle 2 44 week ( surgery ) . During Cycle 1 , participant study visit Weeks 1 , 3 , 5 , 8 . During Cycle 2 , participant study visit month . At every visit , blood ( 2 tablespoon ) draw routine test participant physical exam . Blood ( 2 tablespoon ) draw Weeks 1 , 3 , 5 , 8 , 12 , 24 , 36 , 48 test measure whether certain gene express check participant 's immune system function . Blood ( 2 tablespoon ) draw participant surgery Weeks 12 , 24 , 36 , 48 . If participant take study early , participant blood drawn time well . During Cycle 1 , follow test procedure also perform : If participant 's doctor think safely perform , Week 3 start dabrafenib/trametinib , participant tumor biopsy check study drug affect participant 's immune system cell way participant 's gene express response study drug . If location melanoma easily biopsied clinic , doctor interventional radiology may perform biopsy outside clinic Week 3 instead . The type biopsy participant depend location size tumor . At Week 8 start dabrafenib/trametinib , participant MRI and/or CT scan participant 's brain check status disease . Participant also CT scan chest , abdomen , pelvis . If scan show disease spread grown , participant schedule surgery . Participant continue take study drug day participant 's surgery . During Cycle 2 , follow test procedure perform addition monthly blood draws physical exam : At Weeks 12 , 24 , 36 , 48 , participant EKG ECHO check participant 's heart function . At Weeks 20 , 32 , 44 , participant MRI and/or CT scan participant 's brain , well CT scan chest , abdomen , pelvis , check status disease . Length Treatment : You may receive study drug 1 year . Participant take study disease get bad , study doctor think participant 's best interest , participant unable follow study direction . Participant take study intolerable side effect occur . Participation study participant 's last study visit . Follow-Up Visits : If participant stop take study drug participant complete 52-week schedule , participant follow-up visit least every 3 month surgery 1 year . The following test procedure perform : - Participant physical exam . - Blood ( 2 tablespoon ) draw routine test . - Participant CT scan and/or MRI check status disease . This investigational study . Dabrafenib trametinib FDA approve commercially available treatment melanoma unable remove spread patient V600E/K mutation . The use drug study investigational . Up 78 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>1 . Capable give write informed consent , include compliance requirement restriction list consent form . 2 . Patients must histologically cytologically confirm Stage IIIB/C melanoma . The definition resectability determine patient 's surgical oncologist verify via discussion Multidisciplinary Tumor Conference attend melanoma medical surgical oncology staff . Resectable tumor define significant vascular , neural bony involvement . Only case complete surgical resection tumorfree margin safely achieve defined resectable . 3 . Patients must medically fit enough undergo surgery determine surgical oncology team . 4 . BRAF mutationpositive melanoma ( V600E V600K ) base report Clinical Laboratory Improvement Amendments ( CLIA ) certify laboratory . 5 . Patients must measurable disease , define Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 . 6 . Age &gt; /= 18 year . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 8 . Patients must organ marrow function define : Absolute neutrophil count ( ANC ) &gt; /= 1.5 X 10^9/L ; Hemoglobin &gt; /= 9.5 g/dL ; Platelets &gt; /= 100 X 10^9/L ; prothrombin time/international normalize ratio ( PT/INR ) partial thromboplastin time ( PTT ) &lt; /= 1.5 X upper limit normal ( ULN ) ; Total bilirubin &lt; /= 1.5 X ULN ( isolated bilirubin &gt; 1.5 X ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; /= 2.5 X ULN ^1 ; Albumin &gt; /= 2.5 g/dL ; Creatinine &lt; /=1.5 X ULN 2 OR Calculated creatinine clearance &gt; /= 50 mL/min OR 24hour urine creatinine clearance &gt; /= 50 mL/min . 9 . Male subject must agree use one contraception method list . This criterion must follow time first dose study medication 4 week last dose study medication . However , advise contraception use total 16 week follow last dose ( base lifecycle sperm ) . Methods : ) Abstinence , define sexual inactivity consistent preferred usual lifestyle subject . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . b ) Condom ( nonvaginal intercourse partner male female ) OR c ) Condom occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal agent ( foam/gel/film/cream/suppository ) ( sexual intercourse female ) . 10 . A female subject eligible participate : ) Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/mL estradiol &lt; 40 pg/mL ( &lt; 140 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method Inclusion # 12 wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Continued Inclusion # 11 . 11 . Continued Inclusion # 10 . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . b ) Childbearing potential agrees use one contraception method list Inclusion # 12 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 4 week last dose study medication , must negative serum urine pregnancy test within 14 day prior start dose . 12 . Female Subjects Contraception Methods : ) Abstinence ; b ) Intrauterine device ( IUD ) intrauterine system ( IUS ) meet &lt; 1 % failure rate state product label ; c ) Male partner sterilization prior female subject 's entry study , male sole partner subject ; ) Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal agent ( foam/gel/film/cream/suppository ) . 1 . Currently receive cancer therapy ( chemotherapy , radiation therapy , immunotherapy , biologic therapy ) investigational anticancer drug . 2 . Current use prohibit medication require medication treatment study drug . 3 . Prior BRAF MEK direct therapy ; patient receive prior interferon eligible . 4 . Prior malignancy except follow : adequately treat basal cell squamous cell skin cancer , insitu cervical cancer , thyroid cancer ( except anaplastic ) cancer patient diseasefree 2 year 5 . Any major surgery within last 3 week . 6 . History Central serous retinopathy ( CSR ) retinal vein occlusion ( RVO ) , predispose factor RVO CSR ( e.g . uncontrolled glaucoma ocular hypertension , uncontrolled systemic disease hypertension , diabetes mellitus , history hyperviscosity hypercoagulability syndrome ) . 7 . Presence active gastrointestinal disease condition interfere significantly absorption , distribution , metabolism , excretion drug . 8 . Brain metastases bone metastasis ; patient brain metastasis must receive treatment ( resection SRS ) metastatic focus must stable 8 week prior start study drug . 9 . QTc interval &gt; /= 480 msec ( &gt; /= 500 msec subject Bundle Branch Block ) . 10 . Uncontrolled arrhythmia . 11 . Class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system . 12 . Pregnant lactate female . 13 . Unwillingness inability follow procedure require protocol . 14 . Uncontrolled diabetes , hypertension medical condition may interfere assessment toxicity . 15 . Subjects know glucose 6 phosphate dehydrogenase ( G6PD ) deficiency 16 . Current use anticoagulant ( warfarin , heparin , direct thrombin inhibitor ) therapeutic level .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Neoadjuvant</keyword>
	<keyword>Dabrafenib</keyword>
	<keyword>Tafinlar</keyword>
	<keyword>GSK2118436</keyword>
	<keyword>Trametinib</keyword>
	<keyword>GSK1120212</keyword>
	<keyword>Combination therapy</keyword>
	<keyword>Surgery</keyword>
	<keyword>Adjuvant therapy</keyword>
	<keyword>Melanoma</keyword>
</DOC>